Urinary Cancer Risk Lower in Spironolactone Users

Share this content:
Spironolactone use was associated with 12% decreased odds of prostate cancer in male patients and 19% decreased odds of bladder cancer in female patients.
Spironolactone use was associated with 12% decreased odds of prostate cancer in male patients and 19% decreased odds of bladder cancer in female patients.

Spironolactone use by hypertensive patients is associated with a lower risk of some urinary cancers, according to a new study.

Ya-Wen Chuang, MD, of the Taichung Veterans General Hospital in Taichung, Taiwan, and collaborators analyzed data from 32,167 hypertensive patients with urinary cancers enrolled in Taiwan's National Health Insurance Research Database. In adjusted analyses, spironolactone use was associated with 12% decreased odds of prostate cancer in male patients and 19% decreased odds of bladder cancer in female patients, the investigators reported in the Journal of Hypertension (2017;35:170-177). Use of ACE inhibitors and angiotensin-receptor blockers was not associated with a lower risk.

 

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup